{"doi":"10.1056/oh200801220000004","title":"Unknown","abstract":null,"journal":null,"year":null,"id":655687,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Lenalidomide for Myelodysplasia","abstract":"Among patients with the Δ5q variant of myelodysplasia (MDS), treatment with lenalidomide (Revlimid; an analogue of thalidomide) often decreases the need for red cell transfusions; about 83% of Δ5q MDS patients have erythropoietic responses to lenalidomide. In a recent open-label multi-institutional study, U.S. university and industry investigators evaluated lenalidomide’s effectiveness in treating other types of MDS.\n\nLow-risk non-Δ5q MDS patients were recruited (baseline International Prognostic Scoring System [IPSS] category was confirmed to be low or intermediate-1 in 79%); 22% had clonal cytogenetic abnormalities. All 214 participants received lenalidomide (10 …","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19965766","pmcid":null,"openalex_id":"https://openalex.org/W2626778128","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.33723709,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.jwatch.org/oh200801220000004/2008/01/22/lenalidomide-myelodysplasia","host_type":"journal"}],"fields_of_study":["Acute Myeloid Leukemia Research","Multiple Myeloma Research and Treatments","Protein Degradation and Inhibitors"],"mesh_terms":[],"keywords":["Lenalidomide","Thalidomide","Medicine","Myelodysplastic syndromes","Internal medicine","International Prognostic Scoring System","Oncology","Multiple myeloma","Bone marrow"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T18:35:39.096453Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}